Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase...


Ventrus Biosciences Inc. (VTUS -9.8%) slides after getting FDA feedback requiring a second Phase 3 study of its diltiazem hydrochloride cream - a treatment for anal fissures - before any new drug application can be filed. The drug developer says it expects to file the NDA following completion of the second Phase 3 study, with results expected early Q4 2013, and expects to file an NDA late in Q4 2013 with an anticipated PDUFA date near the end of 2014.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs